This study was based on public use data from the SEER database. The study did not require informed consent from the SEER registered cases, and the authors obtained Limited-Use Data Agreements from SEER.
This study utilized publicly available data from the SEER (Surveillance, Epidemiology, and End Results) database, which is a comprehensive source of information on cancer statistics in the United States. The authors did not need to obtain informed consent from individuals whose cases are registered in the SEER database because the data is anonymized and is meant for public use. Instead, the authors acquired Limited-Use Data Agreements with SEER, which are legal contracts that allow researchers to access and use specific datasets under certain conditions while ensuring that the privacy of the individuals in the database is maintained. This agreement outlines the terms of data use, ensuring that the researchers adhere to guidelines for the ethical handling of data while still enabling them to conduct their research.
Study Type
OBSERVATIONAL
Enrollment
1,776
Surgery
Overall survival
Overall survival refers to the duration of time from the start of diagnosis until death from any cause. It is a common endpoint used in clinical trials and medical research, particularly in oncology, to measure the effectiveness of a treatment or intervention. Overall survival provides a comprehensive picture of how well patients are doing and is often expressed as a percentage or a median time (e.g., the median overall survival time).
Time frame: The estimated time period for assessing events was January 2000 through December 2021. It is the time from random assignment to death from any cause (last follow-up for lost patients; end of follow-up for patients still alive at the end of the study).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.